These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 35180471

  • 1. USP18 reduces paclitaxol sensitivity of triple-negative breast cancer via autophagy.
    Ge X, Zhang D, Song S, Mi Y, Shen Y, Jiang Q, Liang Y, Wang J, Ye Q.
    Biochem Biophys Res Commun; 2022 Apr 09; 599():120-126. PubMed ID: 35180471
    [Abstract] [Full Text] [Related]

  • 2. Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance.
    Li Y, Wang S, Wei X, Zhang S, Song Z, Chen X, Zhang J.
    Cancer Sci; 2019 Feb 09; 110(2):561-567. PubMed ID: 30467925
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
    Lian B, Pei YC, Jiang YZ, Xue MZ, Li DQ, Li XG, Zheng YZ, Liu XY, Qiao F, Sun WL, Ling H, He M, Yao L, Hu X, Shao ZM.
    Theranostics; 2020 Feb 09; 10(24):11092-11109. PubMed ID: 33042272
    [Abstract] [Full Text] [Related]

  • 8. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
    Han J, Yun J, Quan M, Kang W, Jung JG, Heo W, Li S, Lee KJ, Son HY, Kim JH, Choi J, Noh DY, Na D, Ryu HS, Lee C, Kim JI, Moon HG.
    J Mol Med (Berl); 2021 Dec 09; 99(12):1783-1795. PubMed ID: 34626199
    [Abstract] [Full Text] [Related]

  • 9. Neddylation activated TRIM25 desensitizes triple-negative breast cancer to paclitaxel via TFEB-mediated autophagy.
    Zheng B, Qian F, Wang X, Wang Y, Zhou B, Fang L.
    J Exp Clin Cancer Res; 2024 Jun 26; 43(1):177. PubMed ID: 38926803
    [Abstract] [Full Text] [Related]

  • 10. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.
    Han J, Han B, Wu X, Hao J, Dong X, Shen Q, Pang H.
    Toxicol Appl Pharmacol; 2018 Nov 15; 359():55-61. PubMed ID: 30244121
    [Abstract] [Full Text] [Related]

  • 11. Rubioncolin C, a natural naphthohydroquinone dimer isolated from Rubia yunnanensis, inhibits the proliferation and metastasis by inducing ROS-mediated apoptotic and autophagic cell death in triple-negative breast cancer cells.
    Li L, Wang J, Feng L, Fan J, Wang J, Tan N, Wang Z.
    J Ethnopharmacol; 2021 Sep 15; 277():114184. PubMed ID: 33961996
    [Abstract] [Full Text] [Related]

  • 12. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
    Yang N, Wang C, Wang J, Wang Z, Huang D, Yan M, Kamran M, Liu Q, Xu B.
    J Cell Mol Med; 2019 Sep 15; 23(9):6442-6453. PubMed ID: 31359594
    [Abstract] [Full Text] [Related]

  • 13. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
    Liu X, Tang H, Chen J, Song C, Yang L, Liu P, Wang N, Xie X, Lin X, Xie X.
    Oncotarget; 2015 Aug 21; 6(24):20070-83. PubMed ID: 26036638
    [Abstract] [Full Text] [Related]

  • 14. IRE1α inhibitor enhances paclitaxel sensitivity of triple-negative breast cancer cells.
    Wu M, Zhang L, Pi L, Liu L, Wang S, Wu Y, Pan H, Liu M, Yi Z.
    Cell Oncol (Dordr); 2024 Oct 21; 47(5):1797-1809. PubMed ID: 38888849
    [Abstract] [Full Text] [Related]

  • 15. Novel combinatorial autophagy inhibition therapy for triple negative breast cancers.
    Abd El-Aziz YS, Toit-Thompson TD, McKay MJ, Molloy MP, Stoner S, McDowell B, Moon E, Sioson L, Sheen A, Chou A, Gill AJ, Jansson PJ, Sahni S.
    Eur J Pharmacol; 2024 Jun 15; 973():176568. PubMed ID: 38604544
    [Abstract] [Full Text] [Related]

  • 16. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL, Bukhsh MA, Jafry WS, Sexton RE, Bandyopadhyay S, Gorski DH.
    Breast Cancer Res Treat; 2017 Nov 15; 166(2):407-419. PubMed ID: 28780701
    [Abstract] [Full Text] [Related]

  • 17. 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells.
    Satriyo PB, Su CM, Ong JR, Huang WC, Fong IH, Lin CC, Aryandono T, Haryana SM, Deng L, Huang CC, Tzeng YM, Chao TY, Liu HW, Yeh CT.
    Toxicol Appl Pharmacol; 2021 Jul 01; 422():115493. PubMed ID: 33727089
    [Abstract] [Full Text] [Related]

  • 18. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
    Byerly JH, Port ER, Irie HY.
    Breast Cancer Res; 2020 Jun 29; 22(1):72. PubMed ID: 32600444
    [Abstract] [Full Text] [Related]

  • 19. Tanshinone I improves TNBC chemosensitivity by suppressing late-phase autophagy through AKT/p38 MAPK signaling pathway.
    Tang X, Gong J, Ren L, Wang Z, Yang B, Wang W, Wang N.
    Biomed Pharmacother; 2024 Aug 29; 177():117037. PubMed ID: 38959602
    [Abstract] [Full Text] [Related]

  • 20. Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage.
    Reeder A, Attar M, Nazario L, Bathula C, Zhang A, Hochbaum D, Roy E, Cooper KL, Oesterreich S, Davidson NE, Neumann CA, Flint MS.
    Br J Cancer; 2015 Apr 28; 112(9):1461-70. PubMed ID: 25880007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.